Tudor Investment Corp
JBIO

Tudor Investment Corp’s Jade Biosciences JBIO Stock Holding History

Tudor Investment Corp’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-24,200
Closed -$373K – 3597
2025
Q4 		$373K Buy
+24,200
New +$284K ﹤0.01% 2900

Other funds holding JBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Tudor Investment Corp's JBIO Position: Q1 2026 in Review

Tudor Investment Corp sold out of Jade Biosciences (JBIO) in Q1 2026, closing a stake of 24,200 shares — an estimated $373K sold.

Tudor Investment Corp first reported a position in JBIO in Q4 2025 and held it in 1 quarter. The position peaked at $373K in Q4 2025. 120 funds tracked by Wall St. Rank hold JBIO as of Q1 2026.

  • Tudor Investment Corp reported no remaining Jade Biosciences position as of Q1 2026 after selling out during the quarter.
  • Tudor Investment Corp sold 24,200 Jade Biosciences shares in Q1 2026, an estimated $373K.
  • Tudor Investment Corp first reported a position in Jade Biosciences in Q4 2025 and held it in 1 quarter.
  • Tudor Investment Corp's Jade Biosciences position peaked at $373K in Q4 2025.
  • 120 funds tracked by Wall St. Rank held Jade Biosciences as of Q1 2026.

Based on Tudor Investment Corp's 13F filing for Q1 2026, filed 15 May 2026.